Highlights

  • Imricor submitted its final NavTrac and NavTrac-MR Steerable Introducer devices for FDA 510(k) review.
  • The company now has all 510(k) pathway devices either cleared by or under review with the FDA.
  • Imricor's iCMR platform is designed to enable cardiac ablation procedures using real-time MRI guidance.
  • The company reported cash and marketable securities of approximately A$67.5 million at 30 June 2026.

Imricor Medical Systems (ASX:IMR) has submitted the final devices required for its U.S. regulatory pathway, bringing its interventional cardiac MRI (iCMR) platform closer to full product clearance in its largest target market.

The company announced on 20 July 2026 that it had lodged its NavTrac and NavTrac-MR Steerable Introducer devices with the U.S. Food and Drug Administration (FDA) under the 510(k) pathway.

The submission means every Imricor device progressing through the 510(k) process has now either received clearance or is under regulatory review. The milestone moves the company’s focus increasingly toward commercial execution, although broader hospital adoption remains ahead.

What Was Announced?

Imricor confirmed submission of the NavTrac and NavTrac-MR Steerable Introducers, which are steerable sheaths designed to guide cardiac ablation and mapping catheters into the heart.

The NavTrac-MR version includes active tracking coils that allow visualisation inside an interventional MRI suite, while the standard NavTrac is designed for conventional X-ray catheterisation laboratories.

A 510(k) submission is the FDA clearance pathway for medical devices that demonstrate substantial equivalence to an existing approved device. While generally different from full Premarket Approval requirements, the process still requires detailed technical and clinical documentation.

Imricor stated that it has submitted more than 50,000 pages of supporting information to the FDA.

The company confirmed that 14 of the 15 submissions required for its full iCMR platform are now either cleared or under active FDA review.

Earlier in 2026, Imricor received clearance for its NorthStar mapping and ablation system and Vision-MR diagnostic catheter in adult patients, followed by pediatric clearance in July 2026.

Why This Matters

For Imricor (ASX:IMR), completing the 510(k) submission pathway addresses a major regulatory objective that has been central to the company’s U.S. expansion strategy.

The company’s technology allows electrophysiologists to perform cardiac ablation procedures using live MRI guidance rather than traditional X-ray fluoroscopy, potentially reducing radiation exposure for patients and healthcare staff.

With its device portfolio progressing through FDA review, the company is moving closer to offering a broader commercial platform in the U.S. market.

However, regulatory clearance alone does not guarantee commercial adoption. The next stage depends on hospital installations, physician adoption, procedure volumes and broader integration of iMR workflows.

Company Background

Imricor Medical Systems (ASX:IMR) designs and manufactures MRI-compatible cardiac ablation catheters, generators and supporting systems used for treating heart rhythm disorders.

Its core products include the NorthStar mapping and ablation system, Vision-MR diagnostic catheter and NavTrac introducer devices.

The company’s technology enables cardiac procedures under MRI guidance, including applications involving complex arrhythmias such as ventricular tachycardia.

Imricor has commercial approval in Europe through CE marking and has developed an initial international iMR laboratory base.

The United States remains the company’s key expansion opportunity due to the scale of the American cardiac ablation market.

Financial Position

Imricor reported cash and marketable securities of approximately A$67.5 million at the end of Q2 2026, increasing to around A$70 million on a pro forma basis following post-quarter option exercises.

The company also reported a pro forma net cash position of approximately A$100 million when convertible notes are included.

Revenue remains limited at this stage, with quarterly Revenue of approximately US$61,000 reflecting that significant U.S. commercial sales have not yet commenced.

The July 2026 FDA submission announcement did not include updated financial information.

What Comes Next?

The next regulatory milestone for Imricor (ASX:IMR) is the outcome of the final outstanding 510(k) submission for the NavTrac and NavTrac-MR Steerable Introducers.

Beyond regulatory clearance, investors will monitor additional U.S. hospital activations following pediatric NorthStar clearance, progress converting initial hospital relationships into procedure volumes and expansion into adult ablation applications.

The company has not provided a specific timeline for FDA clearance of the remaining submission.

Risks

Imricor (ASX:IMR) remains a small-cap medical technology company with limited current revenue and ongoing reliance on available cash resources. FDA review timelines can vary and clearance is not guaranteed even under the 510(k) pathway. Commercial adoption may take time as hospitals assess Capital requirements and workflow changes associated with iMR laboratories. The company also faces competition from established X-ray-guided ablation systems and remains exposed to Australian dollar and U.S. dollar movements affecting reported financial results.

Investor Takeaway

Imricor has reached an important regulatory milestone by submitting the final devices required for its 510(k) product pathway, reducing one major uncertainty around its U.S. platform development.

The company is now moving toward the commercial execution phase, supported by previous NorthStar clearances and initial U.S. hospital relationships.

However, meaningful revenue growth will depend on hospital adoption, procedure volumes and broader acceptance of MRI-guided cardiac ablation workflows. The remaining FDA review outcome and commercial rollout pace will be key areas to monitor.